HUP0202536A3 - Crystals of the sodium salt of pravastatin - Google Patents

Crystals of the sodium salt of pravastatin

Info

Publication number
HUP0202536A3
HUP0202536A3 HU0202536A HUP0202536A HUP0202536A3 HU P0202536 A3 HUP0202536 A3 HU P0202536A3 HU 0202536 A HU0202536 A HU 0202536A HU P0202536 A HUP0202536 A HU P0202536A HU P0202536 A3 HUP0202536 A3 HU P0202536A3
Authority
HU
Hungary
Prior art keywords
pravastatin
crystals
sodium salt
sodium
salt
Prior art date
Application number
HU0202536A
Other languages
English (en)
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0202536(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Publication of HUP0202536A2 publication Critical patent/HUP0202536A2/hu
Publication of HUP0202536A3 publication Critical patent/HUP0202536A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HU0202536A 1999-08-06 2000-08-04 Crystals of the sodium salt of pravastatin HUP0202536A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9900191A SI20305A (sl) 1999-08-06 1999-08-06 Kristali natrijeve soli pravastatina
PCT/IB2000/001103 WO2001010813A1 (en) 1999-08-06 2000-08-04 Crystals of the sodium salt of pravastatin

Publications (2)

Publication Number Publication Date
HUP0202536A2 HUP0202536A2 (hu) 2003-01-28
HUP0202536A3 true HUP0202536A3 (en) 2003-04-28

Family

ID=20432515

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202536A HUP0202536A3 (en) 1999-08-06 2000-08-04 Crystals of the sodium salt of pravastatin

Country Status (24)

Country Link
US (3) US7078558B1 (hu)
EP (1) EP1200385B2 (hu)
JP (1) JP2003506424A (hu)
KR (2) KR100766928B1 (hu)
CN (1) CN1205172C (hu)
AT (1) ATE287389T1 (hu)
BG (1) BG65368B1 (hu)
CA (1) CA2379335A1 (hu)
CZ (1) CZ2002414A3 (hu)
DE (1) DE60017568T2 (hu)
DK (1) DK1200385T3 (hu)
ES (1) ES2235911T5 (hu)
HR (1) HRP20020106A2 (hu)
HU (1) HUP0202536A3 (hu)
IL (3) IL148050A0 (hu)
NZ (1) NZ516685A (hu)
PL (1) PL365850A1 (hu)
PT (1) PT1200385E (hu)
RU (1) RU2247711C2 (hu)
SI (2) SI20305A (hu)
SK (1) SK1742002A3 (hu)
WO (1) WO2001010813A1 (hu)
YU (1) YU5402A (hu)
ZA (1) ZA200200437B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SK8312002A3 (en) * 1999-12-14 2003-05-02 Biogal Gyogyszergyar Novel forms of pravastatin sodium
JP2002121172A (ja) * 2000-10-16 2002-04-23 Sankyo Co Ltd プラバスタチン又はその薬理上許容される塩の精製方法
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
US6716615B2 (en) 2002-02-27 2004-04-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Strains of saccharaothrix, process for producing pravastatin using the strains and isolation process of (HMG)-CoA reductase
HUP0500074A3 (en) 2002-03-18 2005-07-28 Biocon Ltd Bangalore Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
US20060275219A1 (en) * 2003-06-10 2006-12-07 Taisho Pharmaceutical Co., Ltd. Radial spherical crystallization product, process for producing the same, and dry powder preparation containing the crystallization product
CN1293874C (zh) * 2003-08-18 2007-01-10 李朝晖 以洛伐他汀盐为主要活性成分的中药红曲及其制剂
EP2033636A1 (en) 2003-11-24 2009-03-11 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method of purifying pravastatin
US20080242725A1 (en) * 2004-03-01 2008-10-02 Janez Kerc Pharmaceutical Composition
US20090149533A1 (en) * 2004-08-06 2009-06-11 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
NZ552389A (en) 2004-08-06 2009-05-31 Transform Pharmaceuticals Inc Statin pharmaceutical compositions and related methods of treatment
MX2007009229A (es) * 2005-02-09 2007-09-25 Teva Gyogyszergyar Zartkoruen Metodos para realizar pravastatina de sodio.
JP4895510B2 (ja) * 2005-02-23 2012-03-14 株式会社トクヤマ バリオールアミンの製造方法
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
WO2009148709A1 (en) * 2008-04-16 2009-12-10 University Of Utah Research Foundation Pharmacological targeting of vascular malformations
CN101348476B (zh) * 2008-09-05 2011-05-11 丽珠集团新北江制药股份有限公司 一种制备4,5,6,7-四氢普伐他汀及其钠盐的方法和固体结晶形式
CN101648867B (zh) * 2009-09-04 2012-07-11 天津大学 一种普伐他汀钠晶型及其制备方法和应用
EP2343054A1 (en) 2010-01-04 2011-07-13 LEK Pharmaceuticals d.d. Pellets and microparticles of pravastatin sodium and a process of making them
CN102533893A (zh) * 2010-12-09 2012-07-04 浙江海正药业股份有限公司 一种制备莫那可林j的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS572240A (en) * 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JPS5889191A (ja) * 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
KR100210482B1 (ko) * 1997-04-10 1999-07-15 김종인 스트렙토마이세스엑스포리아투스(streptomycesexfoliatus)yj-118과이를이용한프라바스타틴나트륨의제조방법
US6098031A (en) 1998-03-05 2000-08-01 Gsi Lumonics, Inc. Versatile method and system for high speed, 3D imaging of microscopic targets
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SI20072A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
SI20070A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
PT1154979E (pt) * 1999-02-03 2005-08-31 Inst Drug Res Ltd Processo microbiano para a preparacao da pravastatina
US6682913B1 (en) * 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin

Also Published As

Publication number Publication date
HUP0202536A2 (hu) 2003-01-28
BG65368B1 (bg) 2008-04-30
DE60017568T2 (de) 2006-03-30
SI20305A (sl) 2001-02-28
ES2235911T3 (es) 2005-07-16
DK1200385T3 (da) 2005-05-23
WO2001010813A1 (en) 2001-02-15
IL187261A0 (en) 2008-02-09
CA2379335A1 (en) 2001-02-15
PT1200385E (pt) 2005-04-29
HRP20020106A2 (en) 2003-04-30
US20060183929A1 (en) 2006-08-17
JP2003506424A (ja) 2003-02-18
NZ516685A (en) 2004-01-30
IL148050A0 (en) 2002-09-12
IL148050A (en) 2008-11-03
ZA200200437B (en) 2003-03-26
RU2247711C2 (ru) 2005-03-10
EP1200385A1 (en) 2002-05-02
SI1200385T2 (sl) 2012-02-29
US7078558B1 (en) 2006-07-18
BG106389A (en) 2002-09-30
EP1200385B1 (en) 2005-01-19
KR20070086847A (ko) 2007-08-27
PL365850A1 (en) 2005-01-10
US6740775B1 (en) 2004-05-25
SK1742002A3 (en) 2002-06-04
CN1368948A (zh) 2002-09-11
CN1205172C (zh) 2005-06-08
ATE287389T1 (de) 2005-02-15
CZ2002414A3 (cs) 2002-07-17
DE60017568D1 (de) 2005-02-24
KR20020025204A (ko) 2002-04-03
YU5402A (sh) 2005-03-15
ES2235911T5 (es) 2012-02-27
EP1200385B2 (en) 2011-09-21
SI1200385T1 (en) 2005-08-31
KR100766928B1 (ko) 2007-10-17

Similar Documents

Publication Publication Date Title
HUP0202536A3 (en) Crystals of the sodium salt of pravastatin
HK1026699A1 (en) Crystalline form of omeprazole sodium salt
SG109439A1 (en) Sulfonium salt compounds
EG23980A (en) Potassium salt of (s)-omeprazole
IL159861A0 (en) Crystalline forms of fluvastatin sodium
PL352296A1 (en) Crystalline derivatives of 1-methylocarbapeneme
PL349354A1 (en) Substituted phenethylamine derivatives
EP1117431A4 (en) TREATMENT OF ACIDOSIS
IL150187A0 (en) Novel forms of pravastatin sodium
EG22530A (en) Preparation of substituted piperidin-4-ones
EP1218407A4 (en) USES OF KAPPA-CONOTOXIN PVIIA
PL345542A1 (en) Novel salts of n-tert-butylhydroxylamine
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
IL150245A0 (en) Process for the preparation of sodium salts of statins
PL350963A1 (en) Use of arylalkanoylpyridazines
GB9809350D0 (en) Novel salt
EP1091916A4 (en) CATAPLASM FOR SALT REMOVAL
GB9917344D0 (en) Novel salt
IL145921A0 (en) Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methylaminothio carbonylamino sulfonylphenyl)ethyl) benzamide
HU9904011D0 (en) Novel salts of dipeptid derivatives
AU2678500A (en) Bath salt
GB9929412D0 (en) Use of salt water
EP1210591A4 (en) SEALED COMPARTMENT FILLED WITH ELECTROLYTE
ZA200204500B (en) Forms of pravastatin sodium.
SI0991641T1 (en) Crystalline form of omeprazole sodium salt

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: LEK PHARMACEUTICALS D.D., SI

Free format text: FORMER OWNER(S): LEK PHARMACEUTICAL AND CHEMICAL COMPANY D.D., SI

FD9A Lapse of provisional protection due to non-payment of fees